{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:49:04Z","timestamp":1774550944134,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:00:00Z","timestamp":1590192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:00:00Z","timestamp":1590192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s13555-020-00398-4","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T13:02:39Z","timestamp":1590238959000},"page":"869-879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Paradoxical Skin Reaction to Certolizumab, an Overlap of Pyoderma Gangrenosum and Psoriasis in a Young Woman Treated for Ankylosing Spondylitis: Case Report with Literature Review"],"prefix":"10.1007","volume":"10","author":[{"given":"Anna","family":"Gawdzik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Ponikowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Jankowska-Konsur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zdzis\u0142aw","family":"Wo\u017aniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Maj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-6342","authenticated-orcid":false,"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,23]]},"reference":[{"key":"398_CR1","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fphar.2019.00282","volume":"10","author":"S Garcovich","year":"2019","unstructured":"Garcovich S, De Simone C, Genovese G, Berti E, Cugno M, Marzano AV. Paradoxical skin reactions to biologics in patients with rheumatologic disorders. Front Pharmacol. 2019;10:282.","journal-title":"Front Pharmacol"},{"issue":"3","key":"398_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/dth.12222","volume":"28","author":"FL Sand","year":"2015","unstructured":"Sand FL, Thomsen SF. Off-label use of TNF-alfa inhibitors in a dermatological university department: retrospective evaluation of 118 patients. Dermatol Ther. 2015;28(3):158\u201365.","journal-title":"Dermatol Ther"},{"key":"398_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1600-0560.2012.01894.x","volume":"23","author":"EB Hawryluk","year":"2012","unstructured":"Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alfa antagonists. J Cutan Pathol. 2012;23:481\u20132.","journal-title":"J Cutan Pathol"},{"key":"398_CR4","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/ijd.13691","volume":"56","author":"M Havmose","year":"2017","unstructured":"Havmose M, Thomsen SF. Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases. Int J Dermatol. 2017;56:1087\u2013102.","journal-title":"Int J Dermatol"},{"issue":"4","key":"398_CR5","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1586\/eci.09.18","volume":"5","author":"M Viguier","year":"2009","unstructured":"Viguier M, Richerre P, Bachelez H, Wendling D, Aubin F. Paradoxical adverse effects of anti-TNF alfa treatment: onset or exacerbation of cutaneous disorders. Expert Rev Clin Immunol. 2009;5(4):421\u201331.","journal-title":"Expert Rev Clin Immunol"},{"key":"398_CR6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","volume":"76","author":"G Brown","year":"2017","unstructured":"Brown G, Wang E, Leon A, et al. Tumor-necrosis factor-\u03b1 inhibitor induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. J Am Acad Dermatol. 2017;76:334\u201341.","journal-title":"J Am Acad Dermatol"},{"key":"398_CR7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/tpj.2015.53","volume":"16","author":"T Cabaleiro","year":"2016","unstructured":"Cabaleiro T, Prieto-Perez R, Navarro R, et al. Paradoxical psoriasiform reactions to anti-TNFalfa drugs are associated with genetic polymorphisms in patients with psoriasis. Pharmacogenom J. 2016;16:336\u201340.","journal-title":"Pharmacogenom J"},{"key":"398_CR8","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1111\/ijd.14417","volume":"58","author":"R Arag\u00f3n-Miguel","year":"2019","unstructured":"Arag\u00f3n-Miguel R, Calleja-Algarra A, Vico-Alonso C, et al. Psoriatic alopecia-like paradoxical reaction to certolizumab pegol. Int J Dermatol. 2019;58:e118\u201320.","journal-title":"Int J Dermatol"},{"key":"398_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000342503","volume":"225","author":"F Os\u00f3rio","year":"2012","unstructured":"Os\u00f3rio F, Magro F, Lisboa C, et al. Anti-TNF-\u03b1 induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature. Dermatology. 2012;225:163\u20137.","journal-title":"Dermatology"},{"issue":"1","key":"398_CR10","first-page":"21","volume":"26","author":"E Martina","year":"2017","unstructured":"Martina E, Campanati A, Giuliodori K, Offidani A. Hidradenitis suppurativa in Crohn\u2019s disease during adalimumab therapy: a paradox? Acta Dermatovenerol Alp Pannonica Adriat. 2017;26(1):21\u20133.","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"issue":"4","key":"398_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jamadermatol.2017.5978","volume":"154","author":"HJ Ashchyan","year":"2018","unstructured":"Ashchyan HJ, Butler CD, Nelson CA, et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. JAMA Dermatol. 2018;154(4):409\u201314.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"398_CR12","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.jaad.2017.11.063","volume":"79","author":"HJ Ashchyan","year":"2018","unstructured":"Ashchyan HJ, Nelson CA, Stephen S, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses. Pyoderma gangrenosum and other bowel- and arthritis-associated neutrophilic dermatoses. J Am Acad Dermatol. 2018;79(6):1009\u201322.","journal-title":"J Am Acad Dermatol"},{"key":"398_CR13","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s10067-007-0733-8","volume":"26","author":"K Vandenunere","year":"2007","unstructured":"Vandenunere K, Luyten F, Verschueren P, Lories R, Segaert S, Westhovens R. Pyoderma gangrenosum developing during therapy with TNF-\u03b1 antagonists in a patient with rheumatoid arthritis. Clin Rheumatol. 2007;26:2205\u20136.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"398_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3315\/jdcr.2009.1027","volume":"3","author":"N Jaimes-L\u00f3pez","year":"2009","unstructured":"Jaimes-L\u00f3pez N, Molina V, Arroyave JE, et al. Development of pyoderma gangrenosum during therapy with infliximab. J Dermatol Case Rep. 2009;3(2):20\u20133.","journal-title":"J Dermatol Case Rep"},{"key":"398_CR15","first-page":"447","volume":"11","author":"L Kowalzick","year":"2013","unstructured":"Kowalzick L, Bertolini J, Baumann C, Walther B, Truhm B, Eickenscheidt L. Paradoxical reaction to etanercept: development of pyoderma gangrenosum during therapy of psoriasis arthritis. J Dtsch Dermatol Ges. 2013;11:447\u20139.","journal-title":"J Dtsch Dermatol Ges"},{"key":"398_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00296-017-3861-8","volume":"38","author":"A Skalkou","year":"2018","unstructured":"Skalkou A, Manoli SM, Sachinidis A, et al. Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab. Rheumatol Int. 2018;38:161\u20137.","journal-title":"Rheumatol Int"},{"issue":"1","key":"398_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3109\/09546634.2015.1034075","volume":"27","author":"C Hurabielle","year":"2016","unstructured":"Hurabielle C, Schneider P, Baudry C, Bagot M, Allez M, Viguier M. Certolizumab pegol\u2014a new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn\u2019s disease. J Dermatol Treat. 2016;27(1):67\u20139.","journal-title":"J Dermatol Treat"},{"key":"398_CR18","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/ced.12393","volume":"39","author":"E Cinotti","year":"2014","unstructured":"Cinotti E, Labeille B, Perrot JL, Pallot-Prades B, Cambazard F. Certolizumab for the treatment of refractory disseminated pyoderma gangrenosum associated with rheumatoid arthritis. Clin Exp Dermatol. 2014;39:750\u20131.","journal-title":"Clin Exp Dermatol"},{"key":"398_CR19","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.cgh.2016.07.019","volume":"14","author":"EV Loftus Jr","year":"2016","unstructured":"Loftus EV Jr, Colombel JF, Schreiber S, et al. Safety of long-term treatment with certolizumab pegol in patients with Crohn\u2019s disease, based on a pooled analysis of data from clinical trials. Clin Gastroenterol Hepatol. 2016;14:1753\u201362.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"398_CR20","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/1346-8138.13530","volume":"44","author":"H Koizumi","year":"2017","unstructured":"Koizumi H, Tokuriki A, Oyama N, et al. Certolizumab pegol, a pegylated anti-TNF-\u03b1 antagonist, caused de novo-onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis. J Dermatol. 2017;44(6):723\u20134.","journal-title":"J Dermatol"},{"issue":"5","key":"398_CR21","doi-asserted-by":"publisher","first-page":"e12693","DOI":"10.1111\/dth.12693","volume":"31","author":"GB Kobaner","year":"2018","unstructured":"Kobaner GB, Polat Ekinci A, Yilmaz Z, Copur S. Psoriasiform skin eruption in a patient receiving certolizumab pegol for ankylosing spondylitis: report of a case and review of the literature. Dermatol Ther. 2018;31(5):e12693.","journal-title":"Dermatol Ther"},{"issue":"3","key":"398_CR22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000477957","volume":"9","author":"H Sakai","year":"2017","unstructured":"Sakai H, Nomura W, Sugawara M. Certolizumab pegol- induced folliculitis-like lichenoid sarcoidosis in a patient with rheumatoid arthritis. Case Rep Dermatol. 2017;9(3):158\u201363.","journal-title":"Case Rep Dermatol"},{"issue":"6","key":"398_CR23","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/j.reuma.2017.12.004","volume":"15","author":"L Villalobos-S\u00e1nchez","year":"2019","unstructured":"Villalobos-S\u00e1nchez L, Larena-Grijalba C, Al\u00eda-Jim\u00e9nez A, Sifuentes-Giraldo WA. Certolizumab pegol-induced palmoplantar pustulosis: a case report and review of the literature. Reumatol Clin. 2019;15(6):e163\u20135.","journal-title":"Reumatol Clin"},{"issue":"11","key":"398_CR24","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1038\/ajg.2009.396","volume":"104","author":"F Mocciaro","year":"2009","unstructured":"Mocciaro F, Renna S, Orlando A, Cottone M. Severe cutaneous psoriasis after certolizumab pegol treatment: report of a case. Am J Gastroenterol. 2009;104(11):2867\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"398_CR25","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1001\/archdermatol.2010.225","volume":"146","author":"RQ Klein","year":"2010","unstructured":"Klein RQ, Spivack J, Choate KA. Psoriatic skin lesions induced by certolizumab pegol. Arch Dermatol. 2010;146(9):1055\u20136.","journal-title":"Arch Dermatol"},{"issue":"8","key":"398_CR26","first-page":"40","volume":"5","author":"ML Shelling","year":"2012","unstructured":"Shelling ML, Vitiello M, Lanuti EL, Miteva M, Romanelli P, Kerdel FA. A case of palmoplantar pustulosis induced by certolizumab pegol: new anti-TNF-\u03b1 demonstrates the same class effect. J Clin Aesthet Dermatol. 2012;5(8):40\u20131.","journal-title":"J Clin Aesthet Dermatol"},{"key":"398_CR27","doi-asserted-by":"crossref","unstructured":"Fischer R, DaCunha M, Rajpara A. Certolizumab-induced guttate psoriasiform dermatitis. Dermatol Online J. 2017;23(1).","DOI":"10.5070\/D3231033678"},{"issue":"12","key":"398_CR28","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1080\/00365521.2016.1218541","volume":"51","author":"M Protic","year":"2016","unstructured":"Protic M, Schoepfer A, Yawalkar N, Vavricka S, Seibold F. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels. Scand J Gastroenterol. 2016;51(12):1482\u20138.","journal-title":"Scand J Gastroenterol"},{"key":"398_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/pde.13081","volume":"34","author":"JB Eickstaedt","year":"2017","unstructured":"Eickstaedt JB, Killpack L, Tung J, Davis D, Hand JL, Tollefson MM. Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-tumor necrosis factor alpha agents. Pediatr Dermatol. 2017;34:253\u201360.","journal-title":"Pediatr Dermatol."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00398-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-020-00398-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00398-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T18:12:23Z","timestamp":1666635143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-020-00398-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,23]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["398"],"URL":"https:\/\/doi.org\/10.1007\/s13555-020-00398-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,23]]},"assertion":[{"value":"16 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}